Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid for Bone and Joint Tuberculosis
NCT06811012Phase 2Enrolling by invitation
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of contezolid in Tuberculosis (TB), sponsored by Beijing Chest Hospital. Primary endpoint: Drug concentration in blood and lesion tissue at 14 days. Started Jan 2024; status: enrolling by invitation.
02
Drugs
contezolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06811012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811012.